|
Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
Consulting or Advisory Role - Massive Bio |
Research Funding - Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Immunocore |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); MSD (Inst); Replimune (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
Consulting or Advisory Role - Castle Biosciences |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
|
Consulting or Advisory Role - Certara Inc |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Consulting or Advisory Role - Aptus Clinical; AstraZeneca; Immunocore; PCI Biotech |
|
|
|
|
|
|
Stock and Other Ownership Interests - Immunocore |
|
|
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Iconic Therapeutics; Janssen Oncology; Merck; Novartis |